Moleculin Biotech Inc (MBRX) Annual Balance Sheets

Annual · GAAP · USD millions
Access MBRX quarterly Balance Sheets →
Balance sheet performance over multiple periods helps investors evaluate the financial resilience of Moleculin Biotech Inc.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Assets
Cash & cash equivalent8.88
Cash & Short-term Investments8.00
Prepaid Expense And Other Assets Current0.81
Total Current Assets9.69
Equipment/Property/Plant Net0.08
Intangible Assets11.15
Other Assets, Noncurrent1.21
Operating Lease Right Of Use Asset0.31
Total Assets22.13
Liabilities
Accounts Payable, Current AC3.51
Accrued Liabilities, Current AC3.35
Total Current Liabilities6.85
Total Long-term Debt0.00
Derivative Liability, Noncurrent DE0.04
Other liabilities, Noncurrent0.22
Operating Lease Liability Noncurrent0.22
Total Liabilities7.12
Stockholders' Equity
Aoci Before Tax Attributable To Parent-
Common Stock Value0.00
Additional Paid In Capital Common Stock221.00
Retained Earnings / Accumulated Deficit-206.00
Other Equity0.01
Common Stockholder's Equity15.01
Total Stockholder's Equity15.01
Liabilities & Stockholder's Equity22.13
4 historic quarters locked

Sign in to unlock the full Moleculin Biotech Inc balance sheet history.

About Moleculin Biotech Inc Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001437749-26-008841

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License